Skip to Content

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCTHO0547


Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy (SPORE)

Principal Investigator(s)

Christine Lovly


  • Protocol No. VICCTHO0547
  • Open Date: 12/19/2005
  • Staging: N/A
  • Age Group: Adults
  • Scope: Local
  • Objective: From biopsies of lung cancer, we will determine protein and/or RNA expression patterns capable of predicting tumor response to therapy. We will then characterize which genes and proteins are found to be predictive to help elucidate the molecular biology underlying cancer chemosensitivity.
  • Disease Sites: Lung; Non Small Cell
  • Therapies: Correlative
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT00897650
  • Secondary Protocol No: Not Specified


None Provided.


Ages Eligible for Study:N/A to 120 Years
Genders Eligible for Study:All
Accepts Healthy Volunteers:No


Inclusion criteria
• Diagnosis of suspected lung cancer or lung cancer
Exclusion criteria
• Inability to undergo therapy